CTI BioPharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2019	FY 2018
Period Ending	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Cash & Equivalents	336.67	564.68
Short-Term Investments	5,500	-
Cash & Short-Term Investments	5,837	564.68
Cash Growth	933.63%	-
Other Receivables	67.66	0.25
Receivables	67.66	0.25
Prepaid Expenses	17.19	-
Other Current Assets	427.76	267.4
Total Current Assets	6,349	832.33
Property, Plant & Equipment	271.4	239.17
Other Intangible Assets	170.56	116.58
Other Long-Term Assets	0.12	0.12
Total Assets	6,791	1,188
Accrued Expenses	3.83	1.06
Other Current Liabilities	520.21	112.85
Total Current Liabilities	524.05	113.9
Other Long-Term Liabilities	36.31	24
Total Liabilities	580.51	154.09
Common Stock	5,458	345.7
Additional Paid-In Capital	5,029	1,229
Retained Earnings	-4,335	-1,789
Comprehensive Income & Other	58.57	-2.2
Total Common Equity	6,211	-215.9
Shareholders' Equity	6,211	1,034
Total Liabilities & Equity	6,791	1,188
Net Cash (Debt)	5,837	564.68
Net Cash Growth	933.63%	-
Net Cash Per Share	1297.21	241.70
Filing Date Shares Outstanding	4.5	2.34
Total Common Shares Outstanding	4.5	2.34
Working Capital	5,825	718.42
Book Value Per Share	1380.37	-92.41
Tangible Book Value	6,040	-332.47
Tangible Book Value Per Share	1342.46	-142.31
Machinery	17.78	15.25

Source: S&P Global Market Intelligence. Standard template. Financial Sources.